CAMBRIDGE, Mass. — Takeda today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the United States for patients 17 years of age and older, as prescribed, who use HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase].
The new devices are designed to simplify preparation of the HYQVIA facilitated subcutaneous immunoglobulin (SCIg) infusion by allowing the immunoglobulin and hyaluronidase dual vial units (DVUs) to be transferred from vials without a needle or pooling bag, either in a home environment or a clinical setting. HyHub and HyHub Duo reduce the number of steps required to prepare the infusion of two or more DVUs and minimize the need for additional supplies.
“We collaborated with patients self-infusing HYQVIA and infusion nurses, highlighting their collective need for a simplified preparation process, standardized ancillary supplies, and greater mobility during infusion,” said Uthra Sundaram, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit. “By listening closely to our patients and healthcare partners, we customized these devices to help streamline the infusion preparation experience. The launch of HyHub and HyHub Duo marks the culmination of years of dedicated innovation rooted in real-world needs.”
HyHub and HyHub Duo can reduce the steps required to prepare the immunoglobulin and hyaluronidase components of the HYQVIA infusion by up to half compared to using a pooling bag, depending on the device and number of DVUs. The devices also decrease the ancillary supplies needed and come with an optional carrier bag for added convenience, allowing limited mobility such as moving from room to room.
HyHub and HyHub Duo are available in the U.S. exclusively for use with HYQVIA in patients 17 years and older, as prescribed. Patients interested in these devices should consult their physician and specialty pharmacy for more information. HyHub and HyHub Duo are provided at no additional cost and may only be used after appropriate training from a healthcare professional.
In the United States, HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years and older, and for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy in adults. HYQVIA was first approved in the U.S. in 2014.
